Bosun Hau

Mr. Hau currently is a managing director and co-head of private investments at Tybourne Capital Management, a Hong Kong based global public and private equity investment management firm. Previously, Mr. Hau served as a managing director and partner at Sailing Capital, a Hong Kong and Shanghai based global private equity firm. Mr. Hau also has served as a partner of MVM Partners LLP, a Boston and London based healthcare investment firm, as a management consultant with McKinsey & Company in Southeast Asia, and as an early stage biotechnology investor with S.R. One Ltd, GlaxoSmithKline’s corporate venture group. Earlier in his career, Mr. Hau served as an equity research analyst covering the medical device and pharmaceutical industries for Prudential Securities, Inc. and JP Morgan Securities, Inc. Mr. Hau started his career in sales and marketing at Eli Lilly & Company.

Mr. Hau currently is a member of the boards of directors of Exicure, Inc., and of several private life sciences, fintech, consumer, and TMT companies. Mr. Hau has served as a director or observer to more than 20 publicly listed and private companies. Mr. Hau also is a Board Overseer of Beth Israel Deaconess Medical Center in Boston, a major teaching hospital of Harvard Medical School, and a Leadership Fellow of The Johns Hopkins University.

Mr. Hau received a B.S. in Molecular and Cellular Biology, a B.S.H.S. in Physiological Sciences and a B.A. in Psychology from the University of Arizona, an M.Sc. in Biotechnology from Johns Hopkins University and an M.B.A in Finance and Health Management from the Wharton School at the University of Pennsylvania.